Impact of vitamin D supplementation on the clinical outcomes of COVID-19 pneumonia patients: a single-center randomized controlled trial.

Impact of vitamin D supplementation on the clinical outcomes of COVID-19 pneumonia patients: a single-center randomized controlled trial.

Publication date: Feb 21, 2024

Vitamin D supplementation for infectious diseases has been discussed, but its role in COVID-19 is unclear. Therefore, this study examined the clinical outcomes of COVID-19 pneumonia patients who received vitamin D supplementation. This prospective, open-label, randomized controlled trial was conducted in a university hospital between July 2020 and March 2022. The inclusion criteria were patients aged ≥ 18 years with COVID-19 pneumonia patients. The patients were randomized into two groups: an intervention group receiving vitamin D supplementation (alfacalcidol, two mcg orally daily) until discharge and a control group. The clinical outcomes were pneumonia treatment duration, length of hospital stay, and change in pneumonia severity index between enrollment and discharge. Subgroup analysis was conducted for supplemental oxygen use, high-dose corticosteroid administration, evidence of lymphopenia, C-reactive protein concentration, and total serum vitamin D concentration. Adverse events were monitored. Two hundred ninety-four patients were recruited (147 per group). The two groups did not differ in pneumonia treatment duration to discharge (p = 0. 788) or length of hospital stay (p = 0. 614). The reduction in the pneumonia severity index between enrollment and discharge was more significant in the intervention group (p = 0. 007); a significant decrease was also observed among patients who had C-reactive protein > 30 mg/L (p  30 mg/L) upon treatment initiation. Thai Clinical Trials Registry TCTR20210906005 (retrospectively registered, 6 September 2021).

Open Access PDF

Concepts Keywords
Daily Alfacalcidol
Pneumonia COVID-19
Tctr20210906005 Pneumonia
Therapy SARS-CoV-2
Vitamin D

Semantics

Type Source Name
drug DRUGBANK Vitamin D
disease MESH COVID-19
disease MESH pneumonia
disease MESH infectious diseases
disease IDO intervention
drug DRUGBANK Alfacalcidol
drug DRUGBANK Oxygen
disease VO dose
disease MESH lymphopenia
drug DRUGBANK Trestolone
pathway REACTOME Reproduction
disease MESH morbidity
disease MESH lung injury
disease MESH dehydration
drug DRUGBANK Tocilizumab
disease IDO process
drug DRUGBANK Ritonavir
drug DRUGBANK Favipiravir
disease VO Viruses
disease VO time
disease VO immunization
disease MESH infection
disease VO vaccination
disease MESH secondary infection
disease VO CoronaVac
disease VO vaccine
disease IDO country
disease VO population
drug DRUGBANK Hydroxychloroquine
drug DRUGBANK Ivermectin
disease MESH critically ill
drug DRUGBANK Calcium
drug DRUGBANK Calcitriol
disease VO organ
disease MESH cytokine storms
disease MESH vitamin deficiency
drug DRUGBANK Cholecalciferol
disease VO document
drug DRUGBANK Esomeprazole
disease MESH viral infections
disease IDO cell
disease VO effective
disease MESH clinical course
disease MESH gastrointestinal disorders
disease MESH syndrome
disease MESH sarcoidosis
disease MESH tuberculosis
pathway KEGG Tuberculosis
disease MESH kidney stones
disease MESH contraindication
disease MESH hypersensitivity
disease VO protocol
drug DRUGBANK Prednisolone
drug DRUGBANK Aspartame
drug DRUGBANK Calcium Phosphate
drug DRUGBANK Phosphate ion
disease IDO blood
disease MESH hypercalcemia
disease MESH hyperphosphatemia
disease VO Imovax ID
disease MESH death
disease MESH diabetes mellitus
disease VO vaccinated
disease MESH respiratory failure
drug DRUGBANK Medical air
disease MESH adverse drug reactions
disease MESH obesity
drug DRUGBANK Pentaerythritol tetranitrate
disease IDO symptom
disease VO Hormone
drug DRUGBANK Ergocalciferol
disease VO peritoneum
drug DRUGBANK L-Leucine
disease VO efficiency
disease IDO immune response
disease MESH pulmonary disease
disease MESH tumors
disease MESH complications
disease MESH tachypnea
disease MESH tachycardia
disease IDO production
drug DRUGBANK Calcifediol
disease MESH inflammation
drug DRUGBANK Baricitinib
drug DRUGBANK Etoperidone
disease VO organization
drug DRUGBANK Chloroquine
disease MESH osteoporosis
drug DRUGBANK Vorinostat
disease MESH idiopathic hypoparathyroidism
disease MESH acute myeloid leukemia
pathway KEGG Acute myeloid leukemia
disease VO effectiveness
drug DRUGBANK Angiotensin II

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *